Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial

Autor: Silvestri, G.A., Leake, L., Mazzone, P., Beukemann, M., Midthun, D., McCarthy, P., Sigal, B., Deluca, T., Laberge, F., Fortin, B., Balaan, M., Dimitt, B., Pierre, A., Allison, F., Yarmus, L., Oakjones-Burgess, K., Tanner, N., Ettinger, N., Setchfield, T., Madtes, D., Hubbard, J., McConnell, W., Robinson, K., Lackey, A., Jacques, L., Kuo, E., Markland-Gentles, V., Massion, P., Muterspaug, A., Leach, J., Rothe, K., Rom, W., Pass, H., Sorenson, A., Chesnutt, A., Georgeson, A., Balekian, A., Fisher, J., Murali, R., Overton, A., Desai, N., Levesque, A., Krimsky, W., King, S., Vachani, A., Maletteri, K., Mileham, K., Carter, L., Hong, G., Ma, J., Voelker, K., Barrentine, H., Aronson, R., Henderson, M., Lamberti, J., Krawiecki, C., Case, A., Wilkins, L., Ayers, J.M., Fangmann, K., Landis, J., DeSouza, L., Hammoud, Z., Kah, D., Sanchez, J., Murdoch, L., Silvestri, Gerard A., Tanner, Nichole T., Kearney, Paul, Vachani, Anil, Massion, Pierre P., Porter, Alexander, Springmeyer, Steven C., Fang, Kenneth C., Midthun, David, Mazzone, Peter J.

Publikováno v: In Chest September 2018 154(3):491-500

A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)

Autor: Reck, M., Mileham, K., Paz-Ares, L., Surmont, V., Felip, E., Vinolas, N., Bessudo, A., Clump, D., Decoster, L., Estival, A., Sebastian, M., Chen, H., Chisamore, M., Wagner, V. J., Wagner, A., Smit, E. F. F.

Background: Nivolumab or pembrolizumab is the standard second-line treatment for patients (pts) with advanced NSCLC. Anlotinib is an oral VEGFR, FGFR, PDGFR and c-Kit tyrosine kinase inhibitor. The interaction between tumor immune microenvironment an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3848::762fbc320fc7a2e4bc7618422e691c86
https://hdl.handle.net/20.500.14017/5696831e-55a4-4fb1-b2d3-779a70d263b0

PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial

Autor: Shitara, K., Golan, T., Mileham, K., Voskoboynik, M., Rha, S., Gutierrez, M., Perets, R., Taylor, S., Chen, D., Keenan, T., Rajasagi, M., Healy, J., Shoji, H.

Publikováno v: In Annals of Oncology June 2022 33 Supplement 4:S240-S240

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MA13.05 Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study

Autor: Spigel, D., Jotte, R., Aix, S., Gressot, L., Morgensztern, D., Mccleod, M., Socinski, M., Daniel, D., Juan, O., Mileham, K., West, H., Page, R., Reinmuth, N., Knoble, J., Tian, O., Bhore, R., Wolfsteiner, M., Ong, T. Jin, Gridelli, C., Thomas, M.

Publikováno v: In Journal of Thoracic Oncology October 2019 14(10) Supplement:S301-S301